 | • レポートコード：MRC23Q35977 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、80ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のエンドセリン受容体拮抗薬市場について調査・分析し、世界のエンドセリン受容体拮抗薬市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（アンブリセンタン、ボセンタン、マシテンタン）、用途別セグメント分析（病院薬局、小売店薬局、通信販売薬局）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Gilead Sciences Inc.、Glaxosmithkline Inc.、Sun Pharmaceutical Industries, Inc.、Mylan Pharmaceuticals Inc.、Actavis Pharma, Inc.などが含まれています。 世界のエンドセリン受容体拮抗薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、エンドセリン受容体拮抗薬市場規模を推定する際に考慮しました。本レポートは、エンドセリン受容体拮抗薬の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、エンドセリン受容体拮抗薬に関するビジネス上の意思決定に役立てることを目的としています。 ・エンドセリン受容体拮抗薬市場の概要 - エンドセリン受容体拮抗薬のタイプ別セグメント - 世界のエンドセリン受容体拮抗薬市場規模：タイプ別分析（アンブリセンタン、ボセンタン、マシテンタン） - エンドセリン受容体拮抗薬の用途別セグメント - 世界のエンドセリン受容体拮抗薬市場規模：用途別分析（病院薬局、小売店薬局、通信販売薬局） - 世界のエンドセリン受容体拮抗薬市場規模予測（2018年-2029年） ・エンドセリン受容体拮抗薬市場の成長トレンド - エンドセリン受容体拮抗薬の地域別市場規模（2018年-2029年） - エンドセリン受容体拮抗薬市場ダイナミクス - エンドセリン受容体拮抗薬の業界動向 - エンドセリン受容体拮抗薬市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：アンブリセンタン、ボセンタン、マシテンタン - 世界のエンドセリン受容体拮抗薬のタイプ別市場規模（2018年-2023年） - 世界のエンドセリン受容体拮抗薬のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院薬局、小売店薬局、通信販売薬局 - 世界のエンドセリン受容体拮抗薬の用途別市場規模（2018年-2023年） - 世界のエンドセリン受容体拮抗薬の用途別市場規模（2024年-2029年） ・エンドセリン受容体拮抗薬の地域別市場規模 - 北米のエンドセリン受容体拮抗薬市場規模（2018年-2029年） - アメリカのエンドセリン受容体拮抗薬市場規模（2018年-2029年） - ヨーロッパのエンドセリン受容体拮抗薬市場規模（2018年-2029年） - アジア太平洋のエンドセリン受容体拮抗薬市場規模（2018年-2029年） - 中国のエンドセリン受容体拮抗薬市場規模（2018年-2029年） - 日本のエンドセリン受容体拮抗薬市場規模（2018年-2029年） - 韓国のエンドセリン受容体拮抗薬市場規模（2018年-2029年） - インドのエンドセリン受容体拮抗薬市場規模（2018年-2029年） - オーストラリアのエンドセリン受容体拮抗薬市場規模（2018年-2029年） - 中南米のエンドセリン受容体拮抗薬市場規模（2018年-2029年） - 中東・アフリカのエンドセリン受容体拮抗薬市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Gilead Sciences Inc.、Glaxosmithkline Inc.、Sun Pharmaceutical Industries, Inc.、Mylan Pharmaceuticals Inc.、Actavis Pharma, Inc. ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Endothelin Receptor Antagonist market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Endothelin Receptor Antagonist is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Endothelin Receptor Antagonist is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Endothelin Receptor Antagonist in Hospital Pharmacy is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Endothelin Receptor Antagonist include Gilead Sciences Inc., Glaxosmithkline Inc., Sun Pharmaceutical Industries, Inc., Mylan Pharmaceuticals Inc. and Actavis Pharma, Inc., etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Endothelin Receptor Antagonist, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Endothelin Receptor Antagonist.
The Endothelin Receptor Antagonist market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Endothelin Receptor Antagonist market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Endothelin Receptor Antagonist companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Gilead Sciences Inc.
Glaxosmithkline Inc.
Sun Pharmaceutical Industries, Inc.
Mylan Pharmaceuticals Inc.
Actavis Pharma, Inc.
Segment by Type
Ambrisentan
Bosentan
Macitentan
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Mail Order Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Endothelin Receptor Antagonist companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Endothelin Receptor Antagonist Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Ambrisentan
1.2.3 Bosentan
1.2.4 Macitentan
1.3 Market by Application
1.3.1 Global Endothelin Receptor Antagonist Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Mail Order Pharmacy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Endothelin Receptor Antagonist Market Perspective (2018-2029)
2.2 Endothelin Receptor Antagonist Growth Trends by Region
2.2.1 Global Endothelin Receptor Antagonist Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Endothelin Receptor Antagonist Historic Market Size by Region (2018-2023)
2.2.3 Endothelin Receptor Antagonist Forecasted Market Size by Region (2024-2029)
2.3 Endothelin Receptor Antagonist Market Dynamics
2.3.1 Endothelin Receptor Antagonist Industry Trends
2.3.2 Endothelin Receptor Antagonist Market Drivers
2.3.3 Endothelin Receptor Antagonist Market Challenges
2.3.4 Endothelin Receptor Antagonist Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Endothelin Receptor Antagonist Players by Revenue
3.1.1 Global Top Endothelin Receptor Antagonist Players by Revenue (2018-2023)
3.1.2 Global Endothelin Receptor Antagonist Revenue Market Share by Players (2018-2023)
3.2 Global Endothelin Receptor Antagonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Endothelin Receptor Antagonist Revenue
3.4 Global Endothelin Receptor Antagonist Market Concentration Ratio
3.4.1 Global Endothelin Receptor Antagonist Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Endothelin Receptor Antagonist Revenue in 2022
3.5 Endothelin Receptor Antagonist Key Players Head office and Area Served
3.6 Key Players Endothelin Receptor Antagonist Product Solution and Service
3.7 Date of Enter into Endothelin Receptor Antagonist Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Endothelin Receptor Antagonist Breakdown Data by Type
4.1 Global Endothelin Receptor Antagonist Historic Market Size by Type (2018-2023)
4.2 Global Endothelin Receptor Antagonist Forecasted Market Size by Type (2024-2029)
5 Endothelin Receptor Antagonist Breakdown Data by Application
5.1 Global Endothelin Receptor Antagonist Historic Market Size by Application (2018-2023)
5.2 Global Endothelin Receptor Antagonist Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Endothelin Receptor Antagonist Market Size (2018-2029)
6.2 North America Endothelin Receptor Antagonist Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Endothelin Receptor Antagonist Market Size by Country (2018-2023)
6.4 North America Endothelin Receptor Antagonist Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Endothelin Receptor Antagonist Market Size (2018-2029)
7.2 Europe Endothelin Receptor Antagonist Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Endothelin Receptor Antagonist Market Size by Country (2018-2023)
7.4 Europe Endothelin Receptor Antagonist Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Endothelin Receptor Antagonist Market Size (2018-2029)
8.2 Asia-Pacific Endothelin Receptor Antagonist Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Endothelin Receptor Antagonist Market Size by Region (2018-2023)
8.4 Asia-Pacific Endothelin Receptor Antagonist Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Endothelin Receptor Antagonist Market Size (2018-2029)
9.2 Latin America Endothelin Receptor Antagonist Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Endothelin Receptor Antagonist Market Size by Country (2018-2023)
9.4 Latin America Endothelin Receptor Antagonist Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Endothelin Receptor Antagonist Market Size (2018-2029)
10.2 Middle East & Africa Endothelin Receptor Antagonist Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Endothelin Receptor Antagonist Market Size by Country (2018-2023)
10.4 Middle East & Africa Endothelin Receptor Antagonist Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Gilead Sciences Inc.
11.1.1 Gilead Sciences Inc. Company Detail
11.1.2 Gilead Sciences Inc. Business Overview
11.1.3 Gilead Sciences Inc. Endothelin Receptor Antagonist Introduction
11.1.4 Gilead Sciences Inc. Revenue in Endothelin Receptor Antagonist Business (2018-2023)
11.1.5 Gilead Sciences Inc. Recent Development
11.2 Glaxosmithkline Inc.
11.2.1 Glaxosmithkline Inc. Company Detail
11.2.2 Glaxosmithkline Inc. Business Overview
11.2.3 Glaxosmithkline Inc. Endothelin Receptor Antagonist Introduction
11.2.4 Glaxosmithkline Inc. Revenue in Endothelin Receptor Antagonist Business (2018-2023)
11.2.5 Glaxosmithkline Inc. Recent Development
11.3 Sun Pharmaceutical Industries, Inc.
11.3.1 Sun Pharmaceutical Industries, Inc. Company Detail
11.3.2 Sun Pharmaceutical Industries, Inc. Business Overview
11.3.3 Sun Pharmaceutical Industries, Inc. Endothelin Receptor Antagonist Introduction
11.3.4 Sun Pharmaceutical Industries, Inc. Revenue in Endothelin Receptor Antagonist Business (2018-2023)
11.3.5 Sun Pharmaceutical Industries, Inc. Recent Development
11.4 Mylan Pharmaceuticals Inc.
11.4.1 Mylan Pharmaceuticals Inc. Company Detail
11.4.2 Mylan Pharmaceuticals Inc. Business Overview
11.4.3 Mylan Pharmaceuticals Inc. Endothelin Receptor Antagonist Introduction
11.4.4 Mylan Pharmaceuticals Inc. Revenue in Endothelin Receptor Antagonist Business (2018-2023)
11.4.5 Mylan Pharmaceuticals Inc. Recent Development
11.5 Actavis Pharma, Inc.
11.5.1 Actavis Pharma, Inc. Company Detail
11.5.2 Actavis Pharma, Inc. Business Overview
11.5.3 Actavis Pharma, Inc. Endothelin Receptor Antagonist Introduction
11.5.4 Actavis Pharma, Inc. Revenue in Endothelin Receptor Antagonist Business (2018-2023)
11.5.5 Actavis Pharma, Inc. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details